Lineage Cell Therapeutics (LCTX) Receivables - Net (2011 - 2026)
Lineage Cell Therapeutics' Receivables - Net came in at $790,000 for Q2 2026, up 208.6% from $256,000 a year earlier but down 2.0% from the prior quarter.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Receivables - Net (2011 - 2026) Analysis & Trends
At the end of FY2025, Lineage Cell Therapeutics' Receivables - Net was $891,000, up 39.7% from FY2024.
- Receivables - Net carries a five-year compound annual growth rate of 29.8% (FY2020 to FY2025).
- Going back by year, Receivables - Net was $638,000 in FY2024 (-14.4%), $745,000 in FY2023 (+148.3%), $300,000 in FY2022 (-99.4%) and $50.64 million in FY2021.
- The five-year range for quarterly Receivables - Net is $77,000 (Q1 2024) to $50.64 million (Q4 2021).
- Year-over-year, Receivables - Net has increased for three consecutive quarters, with growth averaging 77.9% over the last eight quarters.
- The fastest year-over-year change in Receivables - Net over five years came in Q3 2021 (growth of 668.8%), and the weakest in Q4 2022 (a decline of 99.4%).
- Business Quant data shows LCTX's Receivables - Net at $806,000 (Q1 2026), $891,000 (Q4 2025) and $127,000 (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn |
| 10 | Lineage Cell Therapeutics | 245.32 Mn | 43.73 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 790,000.00 |
| Mar 31, 2026 | 806,000.00 |
| Dec 31, 2025 | 891,000.00 |
| Sep 30, 2025 | 127,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Mar 31, 2025 | 213,000.00 |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Dec 31, 2023 | 745,000.00 |
| Sep 30, 2023 | 432,000.00 |
| Jun 30, 2023 | 443,000.00 |
| Mar 31, 2023 | 173,000.00 |
| Dec 31, 2022 | 300,000.00 |
| Sep 30, 2022 | 435,000.00 |
| Jun 30, 2022 | 532,000.00 |
| Mar 31, 2022 | 323,000.00 |
| Dec 31, 2021 | 50.64 Mn |
| Sep 30, 2021 | 2.12 Mn |
API Access
Lineage Cell Therapeutics Receivables - Net API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables-net&ticker=LCTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables-net", "ticker": "LCTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables-net&ticker=LCTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();